The treatment may be beneficial in patients whose acute migraine does not respond to standard treatment with intravenous metoclopramide.
Eptinezumab has shown 100% bioavailability when administered intravenously.
Treatment with fremanezumab may help reduce medication overuse and the number of days of acute medication use in individuals with chronic migraine.
Results from the ACHIEVE II study were presented at the American Headache Society's 60th Annual Scientific Meeting.
In the post-hoc analysis, researchers evaluated the time to onset of effect of galcanezumab as well as whether treatment with the study drug was associated with a reduction in migraine headache days.
Dr Richard Lipton and Dr Paul Martin debated the pros and cons of trigger avoidance in patients with migraine headache at the 2018 American Headache Society Annual Scientific Meeting in San Francisco, California.
Individuals with chronic migraine may present with age-related changes in cortical thickness.
The investigators assessed participants for photophobia, unilateral location, phonophobia, exacerbation, nausea, pulsatility, sensory aura, pain level and frequency, visual aura, and allodynia features.
The 2 randomized, phase 3, double-blind studies included in this presentation were the SAMURAI and SPARTAN trials.
In their interim analysis of a 5-year open-label extension trial, study investigators evaluated the safety and tolerability of erenumab treatment in episodic migraine patients who completed ≥3 years of the trial or discontinued treatment.
The CaMEO study is a prospective, longitudinal web-based survey designed to characterize the impact of migraine on aspects of quality of life.
Known risk factors for medication overuse headache include smoking, anxiety, family history of substance abuse, migraine history, depression, and obsessive-compulsive disorder.
A phase 3 study examined a low-dose subcutaneous autoinjection of sumatriptan in the acute treatment of migraines with or without aura in adults.
The comorbidities commonly reported in patients with migraine include those involving cardiovascular, psychiatric, pain, and respiratory conditions, the researchers reported.
Rimegepant is a safe and efficacious pharmacological treatment of acute migraine in adults.
This Phase III, multicenter, double-blind study sought to explore the effect of fremanezumab on the potential reversion from chronic migraine to episodic migraine.
Patients with difficult-to-treat migraine were randomly assigned 1:1 to either 140 mg erenumab or placebo.
This randomized, open-label study examined participant reported outcomes, safety, and tolerability of onabotulinumtoxinA and topiramate in adults with chronic migraines.
More patients in the 100 mg and 300 mg eptinezumab groups achieved a 100% reduction in monthly migraine days over the 12 weeks compared with placebo.
This retrospective study sought to assess migraine patterns in 69 menopausal women between ages 40 and 60 who were treated at Partners Healthcare Hospitals for concurrent migraine headache.
This cross-sectional, observational study sought to evaluate the accuracy of individuals with headache to appraise the relationship between potential trigger factors and headache events.
Fremanezumab has shown efficacy in safely reducing monthly headache days in individuals with chronic migraine.
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Drug Prices Increase More Than Expected After Shortages
- Potentially Inappropriate Opioid Prescribing Tied to Overdose
- Loss of Function Variants in LRKK1 and LRKK2 Not Linked to Parkinson Disease
- Scribes Improve Physician Workflow, Patient Interaction